Document Detail


Middle cerebral arterial thrombosis in a patient with hypofibrinogenemia, 5 days after rFVIIa and FFP infusion.
MedLine Citation:
PMID:  16444445     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A 13-year-old female patient is presented who had hypofibrinogenemia diagnosed as von Willebrand disease at 5 years of age at another hospital. She was admitted to the department of pediatric hematology with a severe headache, vomiting, and progressive right flaccid hemiplegia and lethargy. Contrast-enhanced computed tomography scan showed subdural hematoma in posterior parietal region of the brain and impending cerebellar herniation. She was given fresh-frozen plasma (FFP) and then activated factor VII (rFVIIa), 80 microg/kg was infused for replacement of von Willebrand factor. The subdural hematoma was emergently drained. The results of coagulation tests before infusion of FFP and rFVIIa revealed hypofibrinogenemia, and FFP was given every 48 hours. The patient recovered dramatically in a few days. Five days after rFVIIa infusion, a magnetic resonance angiography-proven right middle cerebral arterial thrombosis developed. It is an interesting point of discussion whether the middle cerebral arterial thrombosis was provoked as a consequence of rFVIIa and FFP infusion.
Authors:
Turkan Patiroglu; Musa Karakukcu
Related Documents :
1687335 - Transcranial doppler ultrasound in brain death: experience in 140 patients.
15503095 - Cerebral microbleeds in patients with hypertensive stroke. topographical distribution i...
19859945 - Three-dimensional micro-mri analysis of cerebral artery development in mouse embryos.
2586155 - A model of proximal middle cerebral artery occlusion in rat.
22780845 - An interesting clinical case: variant of the cephalic vein emptying into the internal j...
1687335 - Transcranial doppler ultrasound in brain death: experience in 140 patients.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis     Volume:  12     ISSN:  1076-0296     ISO Abbreviation:  Clin. Appl. Thromb. Hemost.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2006-01-30     Completed Date:  2006-05-24     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9508125     Medline TA:  Clin Appl Thromb Hemost     Country:  United States    
Other Details:
Languages:  eng     Pagination:  111-3     Citation Subset:  IM    
Affiliation:
Erciyes University Medical School, Department of Pediatric Hematology, Kayseri-Turkey. turkan66@hotmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Afibrinogenemia / complications*,  drug therapy
Blood Component Transfusion / adverse effects*
Factor VII / adverse effects*,  therapeutic use
Factor VIIa
Female
Hematoma, Subdural / chemically induced,  etiology
Humans
Infarction, Middle Cerebral Artery / chemically induced*,  etiology
Magnetic Resonance Angiography
Recombinant Proteins / adverse effects,  therapeutic use
von Willebrand Diseases / complications,  drug therapy
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 0/recombinant FVIIa; 9001-25-6/Factor VII; EC 3.4.21.21/Factor VIIa
Comments/Corrections
Comment In:
Clin Appl Thromb Hemost. 2009 Feb;15(1):125   [PMID:  19150998 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Myocardial infarction and deep venous thrombosis in a young patient with Behçet disease.
Next Document:  Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extra...